Business Description
Pharma Equity Group A/S
ISIN : DK0061155009
Share Class Description:
LTS:0REU: Class ACompare
Compare
Traded in other countries / regions
PEG.Denmark0REU.UK IPO Date
2014-05-28Description
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 1.23 | |||||
| Debt-to-EBITDA | -1.4 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 71.8 | |||||
| 3-Year EPS without NRI Growth Rate | 67.8 | |||||
| 3-Year FCF Growth Rate | 63.6 | |||||
| 3-Year Book Growth Rate | -67.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.09 | |||||
| Quick Ratio | 2.09 | |||||
| Cash Ratio | 0.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -218 | |||||
| Shareholder Yield % | -2.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -60.43 | |||||
| ROA % | -34.36 | |||||
| ROIC % | -37.06 | |||||
| ROC (Joel Greenblatt) % | -81.86 | |||||
| ROCE % | -54.23 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 9.35 | |||||
| Price-to-Tangible-Book | 14.25 | |||||
| EV-to-EBIT | -11.98 | |||||
| EV-to-EBITDA | -12.25 | |||||
| EV-to-FCF | -16.24 | |||||
| Price-to-Net-Current-Asset-Value | 14.25 | |||||
| Earnings Yield (Greenblatt) % | -8.35 | |||||
| FCF Yield % | -6.7 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers